{"commentary":{"count":7,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":4,"podcast":2,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"NCT04277637","nct_id":"NCT04277637","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct04277637. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) or transformed NHL, mantle cell lymphoma (MCL); Waldenströms macroglobulinemia (WM); and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) will receive oral sonrotoclax evaluated as monotherapy.","label":"Sonrotoclax Monotherapy Dose Finding: Part 1","type":"EXPERIMENTAL"},{"description":"Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral sonrotoclax at the RP2D dose to further define the safety profile.","label":"Sonrotoclax Monotherapy Expansion Cohorts: Part 2","type":"EXPERIMENTAL"},{"description":"Participants with R/R MCL, R/R or treatment-naïve (TN) CLL/SLL will receive oral sonrotoclax in combination with zanubrutinib.","label":"Sonrotoclax + Zanubrutinib Combination Therapy Dose Finding: Part 3","type":"EXPERIMENTAL"},{"description":"Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; R/R MCL; R/R or treatment-naïve (TN) CLL/SLL will receive oral sonrotoclax in combination with zanubrutinib at an RP2D dose to further define the safety profile.","label":"Sonrotoclax + Zanubrutinib Combination Therapy Dose Expansion: Part 4","type":"EXPERIMENTAL"},{"description":"Participants with treatment naïve CLL/SLL will receive oral sonrotoclax in combination with obinutuzumab without and with zanubrutinib.","label":"Sonrotoclax + Zanubrutinib Combination Therapy Dose Escalation: Part 5","type":"EXPERIMENTAL"},{"description":"Participants with treatment naïve CLL/SLL will receive oral sonrotoclax in combination with obinutuzumab without and with zanubrutinib at an RP2D dose to further define the safety profile.","label":"Sonrotoclax + Zanubrutinib Combination Therapy Dose Expansion: Part 6","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"conditions":["Mature B-Cell Malignancies"],"enrollment":{"count":437,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sonrotoclax","type":"DRUG"},{"name":"Zanubrutinib","type":"DRUG"},{"name":"Obinutuzumab","type":"DRUG"}],"last_update":"2026-06-22","lead_sponsor":"BeOne Medicines","official_title":"A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Number of Participants Experiencing Serious Adverse Events (SAEs)","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax","timeFrame":"Up to approximately 2 months"},{"measure":"Part 1, Part 3, Part 5: RP2D of Sonrotoclax","timeFrame":"Day 1 to last dose of study drug, an average of 18 months"},{"measure":"Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs","timeFrame":"Up to approximately 2 months"}],"references":[],"start_date":{"date":"2020-03-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies","url":"https://clinicaltrials.gov/study/NCT04277637"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct04277637"}